Enzalutamide treatment and risk for seizures

The “Warnings and Precautions” section of the product prescribing information for enzalutamide (Xtandi) includes the following statement: … READ MORE …

Use of mpMRI and PSMA PET/CT to aid in salvage radiation decision-making

Because the success or failure of salvage radiation (SRT) hinges upon whether micrometastases are already systemic at the time of treatment, evidence that the cancer is still local improves the odds that SRT will be successful. … READ MORE …

Nearly here … generic Viagra (sildenafil) for all …

On Monday December 11 (next week) phase I of the availability of generic Viagra will kick in (here in the US), and those of us who need / want this product to help cope with ED should see a roughly 50 percent drop in the price … READ MORE …

FDA approves key genetic/genomic test for cancer mutations

According to reports from the Associated Press and others, some time late last Thursday the  US Food & Drug Administration (FDA) appears to have approved the use of the FoundationOne CDx genetic/genomic test for patients with “advanced or widely spread cancers.” A media release from Foundation Medicine is also available on line. … READ MORE …

Sexual function after prostate cancer treatment in the MSM community

There is a significant knowledge gap concerning sexual function for prostate cancer patients in the men who have sex with men (MSM) community, because all of the existing assessment tools are designed for the heterosexual population. … READ MORE …

Radium-223 + abiraterone acetate: a potential safety issue

Bayer is to unblind data early from an ongoing randomized clinical trial of radium-223 acetate — on the guidance of the trial’s Independent Data Monitoring Committee (IDMC). … READ MORE …

What’s been on the agenda at the annual meeting of the SUO?

The annual meeting of the Society for Urologic Oncology (SUO) has been been taking place in Washington, DC, over the past couple of days, and yesterday was devoted primarily to prostate cancer. … READ MORE …